This Plain Language Summary of Publication article (PLSP) from Future Oncology, highlights the DESTINY-Breast04 trial, which included 557 adults with advanced HER2-low breast cancer that had worsened after prior chemotherapy. Researchers evaluated whether trastuzumab deruxtecan (T-DXd) was more effective than additional standard chemotherapy in improving cancer outcomes.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer’ and was published in the New England Journal of Medicine.

Visit NEJM using the link to read the original article.